Unprecedented Rise of Mucormycosis in COVID-19 Patients: Urgent Need for Protocol Adaptation and Awareness in India – A Review

Nithya A ¹, Vinoth S V ¹, Ashok Kumar M ¹, Sindhu T ¹

Mucormycosis in COVID-19 patients in India necessitates urgent updates in treatment protocols and public awareness

Abstract

Mucormycosis, a rare fungal infection, has seen a concerning surge in incidence among COVID-19 patients in India. Unlike infectious diseases, Mucormycosis spreads through fungal spores ubiquitous in the environment. COVID-19 patients with diabetes are particularly susceptible, presenting symptoms such as headache, fever, eye pain, nasal congestion, and vision loss. Early diagnosis is crucial for successful treatment. Management involves a multidisciplinary approach, including antifungal medications like liposomal amphotericin-B and posaconazole. However, treatment challenges arise due to limited availability, high cost, and prolonged administration of these drugs. Monitoring blood glucose levels during steroid therapy and raising awareness among healthcare workers and patients are essential preventive measures. Improved ventilation and hygiene practices in hospitals can reduce the risk of exposure to fungal spores. Early detection and prompt treatment are vital in preventing severe outcomes of Mucormycosis. Public education and environmental control measures are essential to mitigate the increasing incidence of this life-threatening fungal infection.

Keywords: Mucormycosis, COVID-19, Diabetes, Steroids, Treatment

References

Cano et al (2020). Impact of corticosteroids in COVID-19 outcomes: systematic review and meta-analysis. Chest.

Draghici et al (2021). COVID-19: disease pathways and gene expression changes predict methylprednisolone can improve outcome in severe cases. Bioinformatics (Oxford, England).

Evert et al (2021). Autopsy findings after long-term treatment of COVID-19 patients with microbiological correlation. Virchows Archiv, 1-12.

Gandhi et al (2020). Mild or moderate Covid-19. New England Journal of Medicine, 383(18), 1757-1766.

Garg et al (2021). Coronavirus disease (Covid-19) associated mucormycosis (CAM): case report and systematic review of literature. Mycopathologia, 1-10.

Garg, D et al (2021). Coronavirus disease (Covid-19) associated mucormycosis (CAM): case report and systematic review of literature. Mycopathologia, 1-10.

Gaur et al (2021). An implant-supported prosthetic rehabilitation of a patient with a bilateral subtotal maxillectomy defect secondary to rhino-orbital-cerebral mucormycosis: A clinical report of a graftless approach. The Journal of Prosthetic Dentistry.

https://conferences.nature.com/event/801e647c-2ffa-4c98-ba1e-135d5cbf4991/summary

https://economictimes.indiatimes.com/news/international/world-news/british-variant-of-covid-19-not-as-severe-as-feared-according-to-the lancet/articleshow/82042830.cms?from=mdr

https://timesofindia.indiatimes.com/city/chennai/181-black-fungus-cases-so-far-in-tn/articleshow/82955642.cms

https://www.business-standard.com/article/current-affairs/india-reports-8-848-mucormycosis-cases-more-amphotericin-vials-allocated-121052200583_1.html

https://www.thehindu.com/opinion/op-ed/slowing-the-pace-of-indias-mucormycosis-threat/article34644652.ece/amp/

https://www.thenewsminute.com/article/tn-government-ropes-experts-study-black-fungus-or-mucormycosis-149492

Ibrahim et al (2007). The iron chelator deferasirox protects mice from mucormycosis through iron starvation. The Journal of clinical investigation, 117(9), 2649-2657.

John et al (2021). When Uncontrolled Diabetes Mellitus and Severe COVID-19 Converge: The Perfect Storm for Mucormycosis. Journal of Fungi, 7(4), 298.

John et al (2021). When Uncontrolled Diabetes Mellitus and Severe COVID-19 Converge: The Perfect Storm for Mucormycosis. Journal of Fungi, 7(4), 298.

Ko et al (2021). A comparison of methylprednisolone and dexamethasone in intensive care patients with COVID-19. Journal of intensive care medicine, 0885066621994057.

Kontoyiannis  and Lewis (2011). How I treat mucormycosis. Blood, The Journal of the American Society of Hematology, 118(5), 1216-1224.

Kostova et al (2021). The Role of Noncommunicable Diseases in the Pursuit of Global Health Security. Health security.

Lamontagne et al (2020). A living WHO guideline on drugs for covid-19. bmj, 370.

Langarizadeh et al (2021). A review on function and side effects of systemic corticosteroids used in high-grade COVID-19 to prevent cytokine storms. EXCLI journal, 20, 339.

Lee et al (1999). Pulmonary mucormycosis: the last 30 years. Archives of Internal Medicine, 159(12), 1301-1309.

Marques et al (2021). The use of posaconazole delayed-release tablets in the successful treatment of suspected mucormycosis in a bottlenose dolphin (Tursiops truncatus) calf. Medical Mycology Case Reports.

Mazzai et al (2021). Imaging features of rhinocerebral mucormycosis: from onset to vascular complications. Acta Radiologica, 0284185120988828.

Miller et al (2021). Successful treatment of Rhizopus arrhizus rhino-orbital-cerebral mucormycosis with isavuconazole salvage therapy following extensive debridement. Medical mycology case reports, 32, 39-42.

Mishra and Mulani (2021). Corticosteroids for COVID-19: the search for an optimum duration of therapy. The Lancet. Respiratory Medicine, 9(1), e8.

Moorthy et al (2021). SARS-CoV-2, Uncontrolled Diabetes and Corticosteroids—An Unholy Trinity in Invasive Fungal Infections of the Maxillofacial Region? A Retrospective, Multi-centric Analysis. Journal of Maxillofacial and Oral Surgery, 1-8.

Muthu et al (2021). Has the mortality from pulmonary mucormycosis changed over time? a systematic review and meta-analysis. Clinical Microbiology and Infection.

Onder et al (2020). Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. Jama, 323(18), 1775-1776.

Panchanatheeswaran et al (2021). Thoracic mucormycosis in immunocompetent patients. Journal of Cardiac Surgery, 36(4), 1183-1188.

Park et al (2021). Mucormycosis originated total maxillary and cranial base osteonecrosis: a possible misdiagnosis to malignancy. BMC Oral Health, 21(1), 1-6.

Prescott and Rice (2020). Corticosteroids in COVID-19 ARDS: evidence and hope during the pandemic. Jama, 324(13), 1292-1295.

Ramanathan et al (2020). Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases. The Lancet Respiratory Medicine, 8(5), 518-526.

Ranjbar et al (2021). Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial. BMC infectious diseases, 21(1), 1-8.

Saad et al (2020). Corticosteroids in the management of pregnant patients with coronavirus disease (COVID-19). Obstetrics & Gynecology, 136(4), 823-826.

Saldanha et al (2021). of the Article: Paranasal Mucormycosis in COVID-19 Patient. Indian Journal of Otolaryngology and Head & Neck Surgery, 1-4.

Singh et al (2021). Diabetes and rhino-orbito-cerebral mucormycosis–A deadly duo. Journal of Diabetes & Metabolic Disorders, 1-7.

Singh et al (2021). Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India. Diabetes & Metabolic Syndrome: Clinical Research & Reviews.

Sittig et al (2021). Cutaneous mucormycosis in a chronic lymphocytic leukemia patient on ibrutinib. IDCases, 24, e01120.

Steinbrink and Miceli  (2021). Mucormycosis. Infectious Disease Clinics, 35(2), 435-452.

Sterne et al (2020). Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. Jama, 324(13), 1330-1341.

Stryker et al (2021). Successful Multi-Modal Treatment of Endobronchial Mucormycosis Infection of Native Lung after Lung Transplant. The Journal of Heart and Lung Transplantation, 40(4), S343-S344.

Szarpak (2021). Mucormycosis-a serious threat in the COVID-19 pandemic?. Journal of Infection.

Tlayjeh et al (2020). Association of corticosteroids use and outcomes in COVID-19 patients: A systematic review and meta-analysis. Journal of infection and public health.

Veisi et al (2021). Rhino-orbital mucormycosis during steroid therapy in COVID-19 patients: A case report. European Journal of Ophthalmology, 11206721211009450.

Verma and Bali (2021). COVID-19 and Mucormycosis of the Craniofacial skeleton: Causal, Contributory or Coincidental?.

Werthman-Ehrenreich  (2021). Mucormycosis with orbital compartment syndrome in a patient with COVID-19. The American Journal of Emergency Medicine, 42, 264-e5.

Zurl et al (2021). Autopsy proven pulmonary mucormycosis due to Rhizopus microsporus in a critically ill COVID-19 patient with underlying hematological malignancy. Journal of Fungi, 7(2), 88.